How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive NSCLC?

Written by Maximilian Hochmair, Otto Wagner Hospital (Vienna, Austria)

In non-small-cell lung cancer (NSCLC), acquired resistance to first-line, first- and second-generation EGFR TKIs is inevitable, predominantly due to the T790M mutation.  The discovery of this mutation prompted the development of third-generation T970M-directed EGFR TKIs including osimertinib, which is used as a second-line treatment.

Osimertinib requires the presence of T790M; therefore, it is important for tumors to be characterized at the first stage of progression to help inform decisions about the optimal treatment sequence.

The latest Editorial published in Future Oncology discusses how we can improve identification of T790M to optimize treatment sequencing decisions for patients with EGFR mutation-positive NSCLC.

View full paper